Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (41-50 of 250) with videos related to

Pageof 25
Sort By:
Cancer|May 16, 2006
Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxisJuan-Manuel Sancho, Josep-Maria Ribera, Albert Oriol, et al.
Leukemia & Lymphoma|April 11, 2003
Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphomaJosé-Tomás Navarro, Josep-María Ribera, Albert Oriol, et al.
Cancer|May 7, 2008
High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patientsAlbert Oriol, Josep-Maria Ribera, Juan Bergua, et al.
Medicina Clinica|September 7, 2017
Second neoplasms in adult patients submitted to haematopoietic stem cell transplantationAnna Torrent, Christelle Ferrá, Mireia Morgades, et al.
European Journal of Haematology|January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM TrialPaul Richardson, Meral Beksaç, Albert Oriol, et al.
Leukemia & Lymphoma|September 16, 2020
Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myelomaAlbert Oriol, Gladys Ibarra, Eugènia Abella, et al.
International Journal of Hematology|May 8, 2007
Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experienceChristelle Ferrà, Pilar Marcos, Maite Misis, et al.
Annals of Hematology|October 2, 2013
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemiaDavid Martínez-Cuadrón, Pau Montesinos, Albert Oriol, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
British Journal of Haematology|July 20, 2016
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myelomaMaría-Victoria Mateos, Miguel Granell, Albert Oriol, et al.
Pageof 25

Showing results (41-50 of 250) with videos related to

Sort By:
Pageof 25
Cancer|May 16, 2006
Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxisJuan-Manuel Sancho, Josep-Maria Ribera, Albert Oriol, et al.
Leukemia & Lymphoma|April 11, 2003
Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphomaJosé-Tomás Navarro, Josep-María Ribera, Albert Oriol, et al.
Cancer|May 7, 2008
High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patientsAlbert Oriol, Josep-Maria Ribera, Juan Bergua, et al.
Medicina Clinica|September 7, 2017
Second neoplasms in adult patients submitted to haematopoietic stem cell transplantationAnna Torrent, Christelle Ferrá, Mireia Morgades, et al.
European Journal of Haematology|January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM TrialPaul Richardson, Meral Beksaç, Albert Oriol, et al.
Leukemia & Lymphoma|September 16, 2020
Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myelomaAlbert Oriol, Gladys Ibarra, Eugènia Abella, et al.
International Journal of Hematology|May 8, 2007
Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experienceChristelle Ferrà, Pilar Marcos, Maite Misis, et al.
Annals of Hematology|October 2, 2013
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemiaDavid Martínez-Cuadrón, Pau Montesinos, Albert Oriol, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
British Journal of Haematology|July 20, 2016
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myelomaMaría-Victoria Mateos, Miguel Granell, Albert Oriol, et al.
Pageof 25